CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 294 enrolled
Drug / intervention
Nivolumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02181738
NCT02181738Phase 2Completed
CompareCT.gov

Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects

Bristol-Myers Squibb·interventional·Posted Jul 4, 2014·Updated Nov 28, 2023

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Doxorubicin, and 2 other interventions for Hodgkin Disease. Completed, enrolled 294 participants across 38 sites in 10 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease
CountriesAustria, Belgium, Canada, Czechia, Germany, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 4, 2014
Enrollment StartAug 12, 2014
Primary CompletionAug 31, 2017
Study CompletionDec 27, 2022
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.0 years ago

Interventions

Nivolumabdrug

Specified dose on specified days

Doxorubicindrug

Specified dose on specified days

Vinblastinedrug

Specified dose on specified days

Dacarbazinedrug

Specified dose on specified days